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Abstract Previous genetic and proteomic studies identi-
ﬁed altered activity of various enzymes such as those of
fatty acid metabolism and glycogen synthesis after a single
toxic dose of valproic acid (VPA) in rats. In this study, we
demonstrate the effect of VPA on metabolite synthesis ﬂux
rates and the possible use of abnormal
13C labeled glucose-
derived metabolites in plasma or urine as early markers of
toxicity. Female CD-1 mice were injected subcutaneously
with saline or 600 mg/kg) VPA. Twelve hours later, the
mice were injected with an intraperitoneal load of 1 g/kg
[U-
13C]-D-glucose.
13C isotopomers of glycogen glucose
and RNA ribose in liver, kidney and brain tissue, as well as
glucose disposal via cholesterol and glucose in the plasma
and urine were determined. The levels of all of the posi-
tional
13C isotopomers of glucose were similar in plasma,
suggesting that a single VPA dose does not disturb glucose
absorption, uptake or hepatic glucose metabolism. Three-
hour urine samples showed an increase in the injected
tracer indicating a decreased glucose re-absorption via
kidney tubules.
13C labeled glucose deposited as liver
glycogen or as ribose of RNA were decreased by VPA
treatment; incorporation of
13C via acetyl-CoA into plasma
cholesterol was signiﬁcantly lower at 60 min. The severe
decreases in glucose-derived carbon ﬂux into plasma and
kidney-bound cholesterol, liver glycogen and RNA ribose
synthesis, as well as decreased glucose re-absorption and
an increased disposal via urine all serve as early ﬂux
markers of VPA-induced adverse metabolic effects in the
host.
Keywords Valproic acid  Stable isotope-based dynamic
metabolic proﬁling (SiDMAP)  [U-
13C6]-D-glucose
1 Introduction
Valproic acid (2-propyl-pentanoic acid, VPA) has clinical
applications in the treatment of a variety of neuropsychi-
atric illnesses such as epilepsy and bipolar disorder (Simon
and Penry 1975; Keane et al. 1982); however, it has been
shown to act as a hepatotoxin in some patients (Eadie et al.
1988). While hepatotoxicity of VPA is not well-under-
stood, numerous studies have identiﬁed several metabolites
that are potentially responsible for the observed toxicity
(Tang and Abbott 1996, 1997; Silva et al. 2004; Gopaul
et al. 2000; 2003). Liver toxicity occurs with an overall
incidence of 1 in 20,000, but a frequency as high as one in
600 or one in 800 is also common in high-risk groups such
as infants below 2 years of age receiving anticonvulsant
polytherapy (Perucca 2002). Early reports suggested
that VPA toxicity might be due to decreased oxidative
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mitochondria. These effects are similar to those of propi-
onate and isovalerate, suggesting a common mechanism of
mitochondrial stress. This in turn may lead to the hepato-
cerebral disorder seen in Reye syndrome (Haas et al. 1981).
In a multi-age rat model (10-, 25-, 40-, 80-day-old),
increasing doses of VPA induced toxicity that was evident
in all age groups after 4 days of treatment. However, tox-
icity patterns in the multi-age study were different within
each age group. The most severe liver and spleen lesions
were found mostly in 10- or 80-day-old rats. While sig-
niﬁcant changes in blood urea nitrogen occurred, altered
alanine aminotransferase and alkaline phosphatase activi-
ties were observed in 10-day-old pups after treatment with
even low doses of VPA (160 mg/kg). The highest VPA
dose (650 mg/kg) caused signiﬁcant decreases in the levels
of serum total protein in older rats (40- and 80-day) (Es-
pandiari et al. 2007).
An integrated metabonomics, proteomics and gene
expression microarray systems biology study in CD-1
female pregnant mice was done after a single subcutaneous
VPA dose of 600 mg/kg body weight (Schnackenberg et al.
2006). Urine, serum, and liver were examined at 6, 12, and
24 h after dosing and showed signiﬁcantly increased glu-
cose concentrations, glycogen phosphorylase activity and
amylo-1,6-glucosidase protein levels. However, the mRNA
levels of 20,000 liver genes did not reveal signiﬁcantly
altered expression at any of the time points examined. The
elevated metabolic enzymes are involved in and control
glucose metabolism to glycogen in liver and other mam-
malian tissues; therefore an early perturbation in the
glycogenolysis process in the VPA exposed liver is evident
(Schnackenberg et al. 2006).
In search of an early toxicity marker and in order to
directly determine organ level metabolite ﬂux and inter-
mediate turnover rates, we used [U-
13C6]-D-glucose as a
tracer. We investigated hepatic glucose production, glucose
dependent futile cycling, cholesterol synthesis, and glucose
disposal via urine after a single VPA dose to female mice.
We report that a single VPA dose in vivo signiﬁcantly
diminished the capacity of the liver to synthesize glycogen,
ribose and cholesterol from glucose. We also observed
urine glucose positional
13C isotopomers consistent with
increased glucose disposal and limited re-absorption from
the primary ﬁltrate. We therefore conclude that the previ-
ously reported decrease in plasma albumin and globulin
levels after prolonged VPA treatment may be the result of
the slow rate of messenger, transfer and ribosomal RNA
backbone ribose synthesis. Decreased glycogen turnover
and diminished cholesterol synthesis rather mimic a gly-
cogen storage and mobilization type disease with functional
changes in sterol synthesis as the earliest detectable mech-
anisms of valproate toxicity in the serum metabolome.
2 Materials and methods
2.1 Animals
Adult (8–9 weeks of age) female CD-1 strain mice (origi-
nally purchased from Charles River; Wilmington, MA, and
maintained at the National Center for Toxicological
Research; Jefferson, AR) were used for all experiments.
Animals were housed in cages (n = 4) and maintained in a
controlled environment (22 C with a 12-h light–dark cycle).
Mice had access to Purina rodent laboratory chow (Purina
Mills,St.Louis,MO)andwateradlibitum.Groupsof8mice
were injected subcutaneously with saline or 600 mg/kg
VPA. Twelve hours later, they were injected with 1 g/kg
body weight [U-
13C]-D-glucose (Cambridge Isotope Labo-
ratories Inc., Andover, MA, [98% isotopic purity and
positional accuracy) intraperitoneally. Tracer (
13C) carbon
labeledglucose inplasma collectedfromthe saphenousvein
(30–50 ll) was determined 60 and 120 min later. The mice
were sacriﬁced180 minafterthe glucose tracerloadbyover
exposure to carbon dioxide. Terminal blood samples were
collected by cardiac puncture, and liver, kidneys, whole
brain(cortex)andurinewerecollectedandfrozenat-80 C.
Samples were sent on dry ice overnight to SiDMAP, LLC
and stored at -80 C until analyzed using GC/MS-based
mass isotopomer analysis. Stable
13C labeled fractions and
isotopomersofglucoseinplasmaandurineweredetermined
according to a standard glucose tolerance test, which was
broadened by glucose
13C isotopomer analysis for deter-
mining glucose absorption, tissue uptake as well as known
hepatic glucose production patterns. Incorporation of the
13C tracer into glycogen, RNA ribose and cholesterol was
alsodeterminedinbrain,kidneyandlivertissues.Allanimal
care procedures followed those in the ‘‘National Research
Council: Guide for the Care and Use of Laboratory Ani-
mals’’ (NRC, 1996 Washington, DC: Institute for
Laboratory Animal Resources) and were approved by the
Animal Care and Use Committee of the National Center for
Toxicological Research.
2.2 Stable Isotope Tracer Studies
Glucose levels from 10 ll plasma and urine were measured
using ACCU-CHEK Advantage (Roche, Manheim, Ger-
many). For mass isotopomer analysis, plasma or urine
(50 ll) samples were deproteinized using 0.1 ml 0.3 N
Barium Hydroxide and Zinc Sulfate solutions (SIGMA, St.
Louis, MO), and the derived glucose fraction was treated
with 1 ml of 30 mg/ml hydroxylamine hydrochloride
(Aldrich, St. Louis. MO) in pyridine (Aldrich, Milwaukee,
WI) (100 C for 1 h) and 0.1 ml acetic anhydride (EMD,
Gibbstown, NJ) (100 C for 0.5 h). This created the aldo-
nitrile pentaacetate derivative for GC/MS analysis (Katz
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123et al. 1991). Glucose molecular ion and its positional iso-
topomers were monitored at the m/z328 ion cluster for
positional
13C mass isotopomer distribution analyses
(MIDA; Fig. 1) (Puchowicz et al. 1999; Xu et al. 2003).
Plasma cholesterol was extracted using 20 ll blood
samples, and tissue cholesterol was extracted by saponiﬁ-
cation of the Trizol (1.0 ml, Invitrogen, Carlsbad, CA) cell
extract after removal of the upper glycogen and RNA
containing supernatant using 30% KOH and 100% ethanol
(300 ll each) for 2 h. Because Trizol contains both phenol
(CAS No.: 108-95-2; 50% by volume) and thiocyanate
(CAS No.: 0022; 30% by volume), which may potentially
interfere with fatty acid and cholesterol GC/MS analyses
we also tested poor Trizol extracts using linear electron
impact as well as cholesterol monitoring GC/MS runs after
sterol extraction with no detectable sterol fragment impu-
rities in Trizol solution only. Sterol extraction from tissues
and plasma was performed using 5 ml petroleum ether
(EMD, Gibbstown, NJ) with repeated shaking for 20 s
three times (Crick and Carroll 1987). The molecular ion of
cholesterol was monitored at m/z386 ion cluster. The
enrichment of acetyl units in plasma and tissue cholesterol
in response to VPA treatment was determined using the
mass isotopomer distribution analysis (MIDA) approach.
Cholesterol synthesis is dependent on glucose carbons
since they are the primary source of acetyl-CoA, the carbon
of which is then incorporated into fatty acids and choles-
terol by de novo synthesis. Acetyl-CoA enrichment
was calculated from the m4/m2 ratio using the formula
m4/m2 = (n - 1)/2(p/q), where n is the number of acetyl
units, p is the
13C labeled precursor acetate fraction and q is
the
12C labeled natural acetate fraction (p ? q = 1) (Lee
1996).
RNA ribose and cellular glycogen were isolated by 2 h
acid hydrolysis in 2 N HCl of the cellular RNA chloro-
form-isopropanol fraction after Trizol-puriﬁcation of cell
extracts (Invitrogen, Carlsbad, CA). Ribose isolated from
RNA, and glucose isolated from cellular glycogen (Powell
et al. 2006) were derivatized to their aldonitrile acetate
form using hydroxyl-amine in pyridine and acetic anhy-
dride as described for plasma glucose above. We monitored
the ion cluster around the m/z256 (carbons 1-5 of ribose,
chemical ionization, CI), in order to ﬁnd the molar
enrichment and positional distribution of
13C labeled car-
bons in total cellular messenger, ribosomal and transfer
RNA-derived ribose (Lee et al. 1998).
2.3 Gas chromatography/mass spectrometry (GC/MS)
Mass spectral data were obtained on the Agilent 5975 Inert
XL Mass Selective Detector connected to an HP6890N
Network gas chromatograph. The settings are as follows:
GC inlet 230 C, transfer line 280 C, MS source 230 C, MS
Quad 150 C. An HP-5 capillary column (30 m length,
250 lm diameter, 0.25 lm ﬁlm thickness) was used for
glucose (plasma, urine or glycogen) and RNA ribose
analysis. A ZB-1 100% polydimethylsiloxane (Phenome-
nex, Torrance, CA., USA) column (15 m length, 250 lm
diameter, 0.25 lm ﬁlm thickness) was used for cholesterol
analysis with speciﬁc temperature programming for sterol
recovery around 25 min retention time.
13C positional
enrichment is presented as
13C M1, M2, …, Mn, where M
represents mass shift in Daltons (D) with an integer indi-
cating the number of
13C carbons replacing
12Ci n
metabolites. For example M2 in glucose indicates two
13C
exchanges with
12C in glucose of plasma, urine or glycogen
glucose as indicated in the text or legends.
2.4 Data analysis and statistical methods
In vivo experiments were carried out using eight mice for
each treatment regimen. Mass spectral analyses were car-
ried out by consecutive and independent automatic
injections of 1 ll sample by the automatic sampler; anal-
yses were accepted only if the standard sample deviation
was less than 1% of the normalized peak intensity among
repeated injections. Data download was performed by three
consecutive manual peak integrations using modiﬁed
(background subtracted) spectra under the overlapping
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Fructose-1, 6-P
Triose-P
Pyruvate
Acetyl-CoA
Glucokinase
[EC 2.7.1.2]
Glucose-6-
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[EC 3.1.3.11]
Pyruvate dehydrogenase
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Phosphoenolpyruvate 
carboxykinase
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[EC 4.1.1.32] 
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[EC 6.4.1.1] OA
Fig. 1 Principles of mass isotopomer analysis (MIDA). The intra-
peritoneally injected [U-
13C6]-D-glucose tracer [shown with all
13C
carbons with red ﬁlled circles] breaks down via enzymatic steps of
glycolysis while via gluconeogenesis it loses, exchanges and dilutes
its carbon skeleton with
12C [shown with empty circles] before
reappearing in plasma via hepatic glucose production or gets
deposited into cellular glycogen in tissues. Various positional
13C
glucose isotopomers observed in plasma or glycogen depict speciﬁc
reactions that contribute to gluconeogenesis, hepatic glucose produc-
tion and glucose dependent futile cycles in the liver (plasma glucose)
or tissues (glycogen glucose obtained from organs) (OA = oxaloac-
etate). (Color ﬁgure online)
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123isotopomer peaks of the total ion chromatogram (TIC)
window displayed by the Chemstation (Agilent, Palo Alto,
CA) software. Statistical analyses were performed using
the parametric unpaired heteroscedastic, two-tailed and
one-tailed independent sample ‘‘t’’ test as indicated with
95% conﬁdence intervals, and P\0.05 was considered to
indicate signiﬁcant differences in glucose carbon metabo-
lism in control or VPA (600 mg/kg) treated mice.
Regression analysis was used to test the dependence
(dependent or response variable) of cholesterol
13C label-
ing and acetyl-CoA enrichment from plasma tracer
[U-
13C6]-D-glucose as the independent variable (explana-
tory variables). Cholesterol
13C labeling and acetyl-CoA
enrichment from the plasma glucose tracer in the regres-
sion equation was modeled as the corresponding constants
random variable representing unexplained variation in the
dependent variable as the null hypothesis. Regression sta-
tistics, analysis of variance (ANOVA) and linear regression
were generated using the best ﬁt model with the least
squares as the primary criteria of VPA toxicity after a
single dose treatment (Lindley 1987).
3 Results
We utilized the mass isotopomer distribution analysis
MIDA approach in order to learn about single dose plasma,
urine or tissue toxicity mechanisms and markers in VPA-
treated mice using a state of the art metabolic tracer
technology and the uniformly
13C labeled [U-
13C6]-D-glu-
cose tracer. Figure 1 shows the concept of the MIDA
approach and the major mass isotopomers generated via
futile cycles by the liver or tissues.
Plasma glucose levels were similar in control and dosed
animals at all time points, namely 181 mg/dl (SD = 10) at
0 min, 319 mg/dl (SD = 9) at 60 min, 278 mg/dl (SD =
11.96) at 120 min and 217 mg/dl (SD = 14) at 180 min in
control, and 186 mg/dl (SD = 13) at 0 min, 322 mg/dl
(SD = 7) at 60 min, 277 mg/dl (SD = 10) at 120 min and
221 mg/dl (SD = 21) at 180 min in VPA treated animals,
respectively. On the other hand, 180 min collected urine
glucose content was increased from 4.9 mg/dl (SD = 1.6;
n = 4) in control mice to 32 mg/dl (SD = 9.2; n = 6;
P\0.001) in VPA-treated animals. Plasma
13C-glucose
labeled fractions including all isotopomers of
13C-labeled
glucose showed almost identical enrichment in control and
VPA treated animals. The
13C labeled fractions in plasma
glucose were 50.9%, 24.9% and 13.2% at 60, 120 and
180 min, respectively, after saline; or 51.9%, 26.7% and
15.3% after VPA treatment as shown in Fig. 2. This indi-
cates that a single VPA dose did not alter tracer glucose
uptake from the intraperitoneal cavity or clearance from the
plasma by host organs.
In the
13C labeled plasma glucose fraction, the injected
[U-
13C6]-D-glucose tracer accounted for 63.1%, 29.4% and
12.9% of total label in saline-treated animals or 61.9%,
25.1% and 12.7% after VPA treatment at 60, 120 and
180 min, respectively. Various isotopomers of plasma
glucose are shown in Fig. 3 indicating similar glucose
absorption and disposal patterns in plasma via hepatic
glucose production and futile cycling in the liver. Control
and VPA treated animals show virtually identical
13C
labeled glucose isotopomer fractions in plasma indicating
similar absorption (M6, glucose tracer injected at time 0),
as well as hepatic glucose production and futile cycles in
liver at all time points.
Although plasma glucose
13C labeling patterns did not
showsigniﬁcantalterationsinresponsetoasingleVPAdose,
plasma cholesterol
13C acetyl-CoA enrichment at 60 min
afterglucoseadministrationwasseverelydecreasedindosed
animals. Glucose-derived acetate enrichment of plasma
cholesterol was 10.93%, 5.83% and 3.19% at 60, 120 and
180 min, respectively, after saline; or 6.52%, 7.76% and
2.82% after 600 mg/kg VPA treatment as shown in Fig. 4.
The summary output of regression statistics between
13C
labeled acetate enrichment in cholesterol from glucose is
shown in Table 1 (control) and Table 2 (VPA treatment).
Such regression statistics indicate that a single VPA dose
severely decreases glucose-derived acetate ﬂux towards
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Fig. 2 Intraperitoneal
13C tracer glucose tolerance test (IPGTT).
Glucose
13C labeled fractions as per cent of total glucose in plasma (Y
axis, Rmn=C1–C6) which includes all
13C-labeled positional isotopo-
mers of glucose at 0, 60, 120 and 180 min (X axis) after tracer load.
Control and VPA-treated animals show virtually identical
13C labeled
glucose fractions in plasma indicating similar absorption and
clearance of tracer glucose at all time points. Control (lower
continuous line) or VPA (upper broken line) glucose
13C-labeled
plasma fractions as independent variables are compared using
regression analysis to corresponding plasma cholesterol
13C-labeled
fractions as the dependent variable to determine glucose to cholesterol
ﬂux by liver metabolism in Tables 1 and 2 (mean ? standard
deviation (SD); n = 8)
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123cholesterolsynthesis asshown by the severelydecreased R
2,
P value and control coefﬁcient (Multiple R), after VPA
treatment of the glucose–cholesterol regression curves.
It is particularly interesting that liver and brain tissue-
bound cholesterol remained relatively low-labeled with
13C
from the glucose tracer, namely 1.49% (SD = 0.114) and
1.41% (SD = 0.1238) in control, or 1.46% (SD = 0.1394;
NS) and 1.47% (SD = 0.1266; NS) after VPA treatment.
On the other hand, kidneys of control animals exhibited a
*2.6-fold higher 3.91% (SD = 0.2061)
13C labeling in
cholesterol, which was decreased to 3.64% (SD = 0.3953;
*P = 0.01514), consistent with a 7% decrease after a
single VPA treatment.
Liver glycogen (Fig. 5a) and RNA ribose (Fig. 5b)
turnover rates were signiﬁcantly decreased after VPA
treatment in comparison with vehicle treated animals. The
[U-
13C6]-D-glucose tracer labeled 22.5% and 13.0% of
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Fig. 3 All
13C labeled glucose isotopomers (including the [U-
13C]-D-
glucose tracer) in plasma. Positional glucose
13C isotopomer fractions
as per cent of the total
13C enriched fraction in plasma (Y axis,
Rmn=C1,2,3,4,5,6) at 0, 60, 120 and 180 min (X axis) after tracer load.
The various isotopomers indicate: M1, pyruvate carboxylase activity;
M2, pyruvate dehydrogenase activity and complete TCA cycle
turnaround; M3, glucose generated from [U-
13C3]-DL-lactate and the
Cori cycle; M4, non-oxidative pentose cycle; and M5, oxidative
pentose cycle (mean; n = 8) (Lee et al. 1991)
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Fig. 4 Acetyl-CoA saturation curves of plasma cholesterol from the
[U-
13C]-D-glucose tracer. Please also see Table 1 (control vehicle
treatment) and Table 2 (VPA treatment) regression statistics
(mean ± standard deviation (SD); n = 8)
Table 1 Regression statistics (A), analysis of variance (B) and linear
regression (C) between
13C glucose and glucose-derived acetate
enrichment in cholesterol using the corresponding 60, 120 and 180
minutes average plasma
13C acetyl-CoA enrichment values in control
vehicle treated animals
Table 2 Regression statistics (A), analysis of variance (B) and linear
regression (C) between
13C glucose and glucose-derived acetate
enrichment in cholesterol using the corresponding 60, 120 and 180
minutes average plasma
13C acetyl-CoA enrichment values in VPA
treated animals
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123liver glycogen; and 19.0% and 11.0% of RNA ribose after
saline and VPA treatment, respectively, during the 180 min
tracer incubation period. In the brains of saline-treated
mice only 1.39% (SD = 0.047) of RNA ribose was labeled
with
13C indicating a slower tissue speciﬁc RNA turnover
compared to that of the liver. One single VPA dose further
reduced brain-speciﬁc RNA
13C labeling to 1.15%
(SD = 0.26), which closely approached signiﬁcance by a
‘‘P’’ value of 0.072 using the more severe two-tailed ‘‘t’’
test. On the other hand, kidney RNA ribose exhibited
1.32% (SD = 0.16) and 1.41% (SD = 0.45; NS)
13C
labeled fractions in control and VPA-treated mice,
respectively. These data suggest a deceleration in the
turnover rate of liver and brain but not the kidneys’ RNA
synthesis after single VPA dosing.
Three-hour aspirated urine samples from the bladder
showed that, of the glucose found in the same amounts
(10 ll) of urine, 35.7% and 55.3% were the injected
13C
glucose tracer (Fig. 6) in control and VPA treated animals,
respectively. The tracer labeled glucose fractions on one or
two carbon positions were much less abundant in the urine,
indicating a signiﬁcant divergence between plasma and
urine glucose isotopomers after VPA treatment. This sug-
gests impaired glucose re-absorption from the primary
glomerular ﬁltrate by the proximal and distal tubules’
glucose transport mechanisms.
4 Discussion
This report describes the fate of the [U-
13C6]-D-glucose
stable isotope substrate tracer in plasma, urine, liver, brain
and kidneys of control and VPA treated mice. We have used
a targeted substrate-product selection approach marking
glucose-derived glycogen, nucleic acid and cholesterol
synthesis and turnover rates, as well as hepatic glucose
production and glucose dependent futile cycling as potential
early functional metabolic biomarkers of VPA-induced
toxicity. The non-invasive and non-radiating
13C glucose
tracer (Buchanan et al. 1998; Garg et al. 2005) allows real-
time quantiﬁcation of synthesis and turnover of selected
metabolites in order to develop the necessary translational
plasma, tissue and urine isotopomer proﬁles routinely
applicable as toxicity biomarkers in humans. Furthermore,
the positional stable
13C isotope-based dynamic metabolic
proﬁling approach has been shown to be valid and to pro-
vide additional information regarding glucose ﬂuxes in
comparison with more traditional metabolic approaches
such as in hereditary hemochromatosis-related abnormali-
ties that lead to cirrhosis, diabetes and other morbidities
(Huang et al. 2007). Changes in vital metabolite ﬂuxes in
response to a single toxic dose of VPA may help in the
determination of the mechanism of toxicity before struc-
tural or morphological damage develops. In short, our tracer
substrate approach utilizes the accurate assessment and
quantiﬁcation of cross-talk and ﬂux alterations among
physiologically vital substrate and product pools and their
disruption by valproate to provide early indications of the
presence and mechanisms of valproate toxicity.
Presently VPA and other drug toxicities, in general, are
assessed by morphological markers of organ damage
including hepatotoxicity and microvesicular steatosis, pro-
teomic and metabonomic methods (Schnackenberg et al.
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Fig. 5 Liver glucose (glycogen) and ribose (total RNA)
13C-labeled
fractions 180 min after tracer load. a Glucose
13C labeled fractions as
per cent of total in liver glycogen (Y axis), b The
13C labeled fraction
in RNA ribose (mean ? standard error of the mean (SEM); n = 8)
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Fig. 6 All
13C labeled glucose isotopomers in aspirated urine from
bladder 3 h after
13C tracer glucose load. Glucose
13C isotopomer
fractions are shown as per cent of the total
13C enriched fraction in
urine (Y axis, Rmn=C1,2,3,4,5,6) in control (C) and valproic acid treated
(VPA) animals (X axis). Control and VPA treated animals showed
distorted
13C labeled glucose isotopomer fractions in urine indicating
increased tracer disposal via urine (M6, [U-
13C6]-D-glucose tracer
injected at time 0; average ? SEM, n = 8; *P = 0.016) in VPA
treated animals. The various isotopomers indicate: M1, pyruvate
carboxylase activity (*P = 0.029); M2, pyruvate dehydrogenase
activity and complete TCA cycle turnaround; M3, glucose generated
from [U-
13C3]-DL-lactate and the Cori cycle; M4, non-oxidative
pentose cycle; and M5, oxidative pentose cycle
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1232006) and gene expression proﬁles (Lee et al. 2007). In the
study by Lee et al. (2007), after microarray analysis of 1910
genes and hierarchical clustering, it was evident that gene
expression data show striking changes in the synthesis of
enzyme proteins associated with fatty acid and steroid
metabolism. These authors used two doses of VPA (100 and
1000 mg/kg) and examined gene expression at several time
points. They observed changes in gene expression that were
dependent both on VPA dose as well as time after treatment.
Some of the genes responded soon after treatment (early
genes), while others responded only at the later time points.
VPA treatment characteristically up- or down-regulated
(cutoff[1.5-fold) 60 genes involved in lipid metabolism
and biological pathways for biosynthesis of triglycerides
and cholesterol, catabolism of fatty acids, and lipid trans-
port. One of the ﬁrst reports to match a hepatotoxic VPA
dose (200 or 600 mg per kg, i.p.) with its functional and
structural changes in rats revealed an immediate, dose-
dependent and prolonged increase in bile salt-independent
bile ﬂow with a decrease in biliary cholesterol and
phospholipid output. At 3 and 5 h, marked structural chan-
ges were evident in hepatocytes, including formation of
autophagic vacuoles, engulﬁng morphologically altered
mitochondria and occasional peroxisomes (Jezequel et al.
1984). In our study VPA-treated liver exhibited decreased
acetyl-CoA
13C enrichment from iglucose to cholesterol by
more than 40% in easily accessible plasma samples only
12 h after a single VPA dose, indicating a non-glucose
responsive liver after a single dose of 600 mg(-kg) VPA.
This rapid toxicity marker is based and herein demonstrated
to be applicable in vivo on the ﬁnding that a single VPA
treatment already decreases the rate constant (Sarwal et al.
1989; Comi and Hamilton 1994) of glucose-derived
13C-labeled acetate’s ﬂux towards sterol synthesis.
An important functional impairment of liver cells is
evident by the signiﬁcantly decreased glycogen turnover
with a concomitant and comparable decrease in RNA ribose
synthesis. In a previous report, VPA at 200 mg/kg caused a
profound reduction in liver glycogen stores in infant mice
(Thurston et al. 1981), which is consistent with our previous
results of a decrease in liver glucose after VPA adminis-
tration (Schnackenberg et al. 2006). Our present results
showed a more than 40% decrease in glycogen
13C labeling
from plasma tracer glucose after an intraperitoneal tracer
load. This decreased glycogen turnover points to one of the
central mechanisms of VPA-induced hepatotoxicity,
namely the decrease in glucose storage capacity in the
satiety state. Although plasma glucose
13C isotopomer
fractions did not yet reveal impaired hepatic glucose pro-
duction or glucose dependent futile cycling, we believe that
repeated treatments with VPA and a more prolonged
depletion of liver glycogen could in fact impair gluconeo-
genesis and blood glucose control.
The liver is responsible for the production of the majority
of plasma albumin and globulin, as well as various spe-
cialized proteins in host defense (such as complement
cascade globulins) and of the extrinsic pathway of blood
coagulation. In fact, delayed synthesis and activation of
factors II, V, VII, X and ﬁbrinogen are important measures
of liver damage. Additionally, the signiﬁcant decrease in
liver and, less extensively, brain RNA ribose synthesis by
VPA is another key mechanism of organ damage and
available as an early signal of organ toxicity. Decreased
RNA turnover may have far reaching and severe functional
consequences affecting gene expression, protein synthesis
and metabolism. Consequent abrupt decreases in protein
synthesis and turnover can now sensitively be measured by
deuterium labeled water as the tracer and matrix assisted
timeofﬂight(MALDI-TOF)technologyforamoreaccurate
determinationofdrug-interruptedlivercellproteinsynthesis
of speciﬁc classes and function (Xiao et al. 2008). Func-
tional protein analysis is a method that will likely increase
the power of drug toxicity studies in the near future.
Our careful analysis of urine glucose
13C isotopomers
provides another easy-to-obtain biomarker for VPA toxicity
in the kidney. The plasma distribution of glucose
13C iso-
topomers is virtually identical in control and VPA-treated
mice and follows the logical progressionof higher[U-
13C6]-
D-glucose tracer 60 min after dosing, with increases in the
isotopomers of gluconeogenesis at 120 and 180 min. Three
hours after glucose dosing, the injected tracer is still the
highest in the urine of the VPA group, while in controls
much less of the tracer was recovered. These ﬁndings
strongly suggest that VPA inhibits glucose re-absorption by
the proximal tubules of the kidneys (Nowak and Schnell-
mann 1995; Cohen and Little 1976), resulting in a strikingly
different urine isotopomer proﬁle 3 h after glucose tracer
load. While inhibited gluconeogenesis and glucose pro-
duction by VPA in proximal tubules may be the cause of the
uniformly decreased
13C M1, M2 and M3 fractions in urine,
the high fraction of the injected tracer (M6 fraction) more
likely indicates decreased re-absorption of glucose from the
primary ﬁltrate in the proximal tubules.
The anticonvulsant activity of VPA may be due, in part,
to alterations in brain glucose metabolism. It has previously
been shown that VPA interferes with brain glucose trans-
port and metabolism by inhibiting glucose transporter-1
(GLUT1) activity in normal and GLUT1-deﬁcient eryth-
rocytes by 20–30%. This causes a corresponding reduction
in Vmax of glucose transport in primary astrocytes as well
as in normal and GLUT1-deﬁcient ﬁbroblasts. VPA
inhibited glucose transport by 20–40%, and this was
accompanied by an up to 60% down regulation of GLUT1
mRNA expression (Wong et al. 2005). Additionally, fruc-
tose-1,6-bisphosphate (F1,6BP) shifts the metabolism of
glucose from glycolysis to the pentose phosphate pathway
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acute seizures induced by pilocarpine, kainic acid, or
pentylenetetrazole. This is similar to the action of
2-deoxyglucose (2-DG; an inhibitor of glucose uptake and
glycolysis) and VPA (Lian et al. 2007), which not only
alter brain function but also vastly affect the disposal of
glucose via urine, based on our tracer substrate-based
metabolomics study.
It is also of particular physiological and toxicological
importance that the kidneys are primary organs of HDL-
cholesterol storage, catabolism and disposal, based on the
over 2.5-fold increase in
13C labeled cholesterol in the
kidneys in comparison with liver and brain tissues, as well
as by showing similar response to VPA induced changes in
plasma cholesterol, as shown in this 3-h tracer substrate
study. It has long been known that patients homozygous for
Tangier disease (a familial high-density lipoprotein deﬁ-
ciency) have a near absence due to selective catabolism of
plasma HDL apoA-I by the kidneys (Lee et al. 2005). This
is the result of mutations in the ATP-binding cassette, sub-
family A, member 1 (ABCA1), which is a prominent
member of the HDL assembly membrane transporters
(Slatter et al. 2008). With cholesterol as its substrate, this
protein functions as a lipid efﬂux pump in the cellular
cholesterol removal pathway. It is obvious based on our
study that the selective catabolism of circulating HDL in
the kidneys and its
13C cholesterol moiety leave a promi-
nent stable isotope ﬁngerprint on the kidneys’ cholesterol
13C silhouette, which opens new avenues to study glu-
cose ? cholesterol carbon exchange, disposal and
substrate product cross-talk in future in vivo drug toxicity,
efﬁcacy and mechanism of action studies.
Renal tubular glucose re-absorption is performed chieﬂy
by GLUT1 in the basolateral membrane in the proximal
tubules in rats and humans (Linden et al. 2006). The
ﬁnding in the current study of decreased re-absorption of
glucose from the proximal tubules might be due to a
decrease in kidney GLUT1 expression and activity. This
decreased expression might also occur in the brain and
might be the mechanism whereby valproate inhibits glu-
cose transport in the brain for the effective control of
seizures (Cornford and Oldendorf 1986). The
13C glucose
positional isotopomer proﬁle of urine may serve as the
most effective, least invasive and easiest to analyze bio-
marker to determine the whole body response to drugs
targeting glucose transport.
4.1 Concluding remarks
The pharmaceutical industry is challenged to ﬁnd bio-
markers for early drug toxicity while attempting to achieve
maximum drug efﬁcacy to control various human diseases.
We showed that VPA produces liver toxicity by disrupting
ﬂux of tracer glucose-derived acetate and its disposal via
plasma cholesterol. The decreased re-absorption of glucose
from the proximal tubules may indicate decreased glucose
transport in the brain which may control seizures and
psychiatric mental swings in bipolar disease.
13C tracer
substrate-based metabolomics may improve toxicology by
uncovering defective metabolite ﬂuxes on the basis of
decreased correlation between tracer substrate ﬂow into
plasma products requiring liver passage and metabolism.
As toxic drugs decrease rate constants and thus regression
coefﬁcients, select metabolic tracer substrates and their
products may be used to depict and predict how gene
expression proﬁles translate through metabolic interactions
into the functional consequences of organ and biological
systems activity, thereby avoiding iatrogenic harm and
choosing optimal medical interventions in the clinic. Cut-
off regression coefﬁcients based on known toxic drug
induced regression parameters need to be determined.
Additionally, tracer methodology could be useful to mon-
itor individual responses to drugs and to detect early signs
of toxicity prior to irreversible organ damage or loss of life.
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